We have located links that may give you full text access.
COMPARATIVE STUDY
JOURNAL ARTICLE
Increasing Biopsy Utilization for Renal Cell Carcinoma Is Closely Associated With Treatment.
Urology 2015 November
OBJECTIVE: To describe recent temporal trends in biopsy use for renal cell carcinoma and to identify factors associated with biopsy.
MATERIALS AND METHODS: Renal cell carcinoma diagnoses from 2003 to 2011 were identified using the National Cancer Data Base. Cases were classified by traditional (clinical stage T4, N1, or M1, or history of other malignancies) or expanded biopsy indications. Time trends were plotted, and multivariate analysis was performed to identify factors associated with biopsy.
RESULTS: Of 171,406 eligible patients, we identified 21,019 patients (12.3%) who were biopsied. We observed a significant increase in biopsy usage with time for both the traditional (range, 16.7%-20.6%) and expanded (range, 6.9%-10.9%) subgroups (P < .01 for the trends). By the end of the study period, expanded indications accounted for most biopsies. By far, eventual treatment was the strongest factor associated with biopsy utilization for either subgroup. Compared with patients treated with partial nephrectomy, the odds of being biopsied were 2.7-4.3, 6.0-9.8, 14.6-23.0, and 3.0-4.4 times higher for patients managed with observation, cryoablation, radiofrequency ablation, or chemotherapy (including targeted therapy), respectively (P < .01). In the expanded-indications subgroup, other factors significantly associated with biopsy included sex, race, income, insurance, travel distance, case volume, region, and tumor size (P < .01 for all). Other significant factors in the traditional-indications subgroup were income, region, and Charlson score (P < .01 for all).
CONCLUSION: In recent years, renal cell carcinoma biopsy has been increasingly used in patients with traditional and expanded indications. Its use is strongly associated with treatment and treatment-related factors.
MATERIALS AND METHODS: Renal cell carcinoma diagnoses from 2003 to 2011 were identified using the National Cancer Data Base. Cases were classified by traditional (clinical stage T4, N1, or M1, or history of other malignancies) or expanded biopsy indications. Time trends were plotted, and multivariate analysis was performed to identify factors associated with biopsy.
RESULTS: Of 171,406 eligible patients, we identified 21,019 patients (12.3%) who were biopsied. We observed a significant increase in biopsy usage with time for both the traditional (range, 16.7%-20.6%) and expanded (range, 6.9%-10.9%) subgroups (P < .01 for the trends). By the end of the study period, expanded indications accounted for most biopsies. By far, eventual treatment was the strongest factor associated with biopsy utilization for either subgroup. Compared with patients treated with partial nephrectomy, the odds of being biopsied were 2.7-4.3, 6.0-9.8, 14.6-23.0, and 3.0-4.4 times higher for patients managed with observation, cryoablation, radiofrequency ablation, or chemotherapy (including targeted therapy), respectively (P < .01). In the expanded-indications subgroup, other factors significantly associated with biopsy included sex, race, income, insurance, travel distance, case volume, region, and tumor size (P < .01 for all). Other significant factors in the traditional-indications subgroup were income, region, and Charlson score (P < .01 for all).
CONCLUSION: In recent years, renal cell carcinoma biopsy has been increasingly used in patients with traditional and expanded indications. Its use is strongly associated with treatment and treatment-related factors.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app